Core Viewpoint - The article discusses the performance of the Shanghai Composite Index and the Hang Seng Index on August 14, highlighting the decline in both indices and providing insights into the pricing and premium of XD Zhaoyan New Drug Research Center Co., Ltd. in the A-share and H-share markets [1] Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. (stock code: 603127.SH/6127.HK) was established in 1995 and is a specialized contract research organization (CRO) focused on drug development services [1] - The company is headquartered in Beijing and has subsidiaries in multiple locations including Suzhou, Chongqing, Guangzhou, Wuxi, Wuzhou, Nanning, Yunnan, Shanghai, California, and Boston [1] - Zhaoyan New Drug has established a quality management system that complies with international standards and holds various certifications including CNAS/ILAC-MRA, NMPA (China), FDA (USA), PMDA (Japan), MFDS (Korea), OECD GLP, and AAALAC (animal welfare) [1] Market Performance - On August 14, the Shanghai Composite Index fell by 0.46% to close at 3666.44 points, while the Hang Seng Index decreased by 0.37% to close at 25519.32 points [1] - XD Zhaoyan New A-shares closed at 32.21 yuan, down 5.74%, and H-shares closed at 24.56 HKD, down 1.52% [1] - The A/H premium for XD Zhaoyan New reached 43.47%, ranking it 79th among AH shares, indicating that H-shares are relatively cheaper compared to A-shares [1]

Company Overview - Beijing Zhaoyan New Drug Research Center Co., Ltd. (stock code: 603127.SH/6127.HK) is a specialized drug research and development service outsourcing company (CRO) established in 1995, headquartered in Beijing [4] - The company has subsidiaries in multiple locations including Suzhou, Chongqing, Guangzhou, Wuxi, Wuzhou, Nanning, Yunnan, Shanghai, California, and Boston, and has established a quality management system compliant with international standards [4] - Zhaoyan New Drug provides a one-stop service for non-clinical pharmacology and toxicology research, clinical trials, and drug safety monitoring, as well as evaluations for veterinary drugs, pesticides, and medical devices [4] Financial Performance - As of March 31, 2025, Zhaoyan New Drug reported total operating revenue of 287 million yuan, a year-on-year decrease of 11.54%, while net profit attributable to shareholders was 41.12 million yuan, a year-on-year increase of 115.11% [2] - The company's gross profit margin stands at 28.61%, and its asset-liability ratio is 13.96% [2] Stock Performance - Over the past month, Zhaoyan New Drug has seen a cumulative increase of 30.66%, and a year-to-date increase of 35.83%, outperforming the Hang Seng Index by 17.51% [2] - The stock closed at 14.18 HKD per share on May 30, with a trading volume of 36.01 million shares and a turnover of 507 million HKD, reflecting a volatility of 22.52% [1] Industry Valuation - The average price-to-earnings (P/E) ratio for the pharmaceutical and biotechnology industry is 5.64 times, with a median of 5.97 times, while Zhaoyan New Drug's P/E ratio is 22.4 times, ranking 52nd in the industry [3] - Comparatively, other companies in the industry have significantly lower P/E ratios, such as Qingdao Haier Biomedical (0.68 times) and King’s Ray Biotechnology (1.22 times) [3] Upcoming Events - The company plans to distribute a dividend of 0.03 RMB per share (approximately 0.032512 HKD) for the fiscal year ending in 2024, with the ex-dividend date set for June 26, 2025, and the payment date on August 31, 2025 [5]